← Back to Search

Platelet-based Treatment

Platelet Therapy for Degenerative Disc Disease

N/A
Recruiting
Led By Christopher Centeno, MD
Research Sponsored by Regenexx, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Voluntary signature of the IRB approved Informed Consent
Skeletally mature Male or Female ages 25 to 65
Timeline
Screening 5 days
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is comparing two different treatments for degenerative disc disease, both of which involve platelets. One group will receive the treatment 4 weeks apart, and the other group will receive sham procedures.

Who is the study for?
This trial is for adults aged 25 to 65 with painful Degenerative Disc Disease confirmed by MRI and physical exam, who have not improved after specific back pain treatments and are potential candidates for lumbar surgery. It excludes smokers, those with untreated psychological conditions contributing to chronic pain, inflammatory diseases like rheumatoid arthritis, recent steroid injections, anticoagulant or immunosuppressive medication users, opioid users or drug abuse history within six months.Check my eligibility
What is being tested?
The study tests two platelet-based treatments: Platelet-rich plasma (PRP) and Platelet lysate (PL), against a sham procedure (a fake treatment that seems real) in patients with degenerative disc disease. Treatments are given four weeks apart to see which is more effective at relieving back pain.See study design
What are the potential side effects?
While the trial information does not specify side effects, common ones from similar procedures may include temporary increase in back pain, infection risk at injection site, nerve damage risks associated with spine procedures and possible allergic reactions to the substances used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 25 and 65 years old.
Select...
I have back pain due to disc disease without major spine alignment issues.
Select...
I have chronic back or leg pain that hasn't improved with standard treatments for over 6 months.
Select...
My MRI and physical exam show I have painful degenerative disc disease.
Select...
I am a candidate for lumbar spine surgery.

Timeline

Screening ~ 5 days
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 5 days for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Modified Single Assessment Numerical Evaluation (SANE) scores
Secondary outcome measures
Functional Rating Index (FRI)
Incidence rate of adverse events
Incidence rate of surgical/other treatment interventions
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Platelet treatmentExperimental Treatment1 Intervention
A series of two treatments spaced 4 weeks apart that include platelet-rich plasma (PRP). platelet lysate (PL), and platelet poor plasma (PPP).
Group II: Sham procedurePlacebo Group1 Intervention
A series of two sham procedures spaced 4 weeks apart.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Platelet-Rich Plasma (PRP) therapy for Degenerative Disc Disease works by promoting healing and regeneration through the release of growth factors and cytokines, which can enhance tissue repair and reduce inflammation. This is crucial for DDD patients as it may alleviate pain and improve spinal function. Other common treatments include physical therapy, which strengthens the muscles supporting the spine, and surgical options like spinal fusion, which stabilizes the affected vertebrae to reduce pain and improve mobility.

Find a Location

Who is running the clinical trial?

Regenexx, LLCLead Sponsor
14 Previous Clinical Trials
50,803 Total Patients Enrolled
Christopher Centeno, MDPrincipal InvestigatorCenteno-Schultz Clinic
12 Previous Clinical Trials
50,355 Total Patients Enrolled

Media Library

Platelet lysate (PL) (Platelet-based Treatment) Clinical Trial Eligibility Overview. Trial Name: NCT05287867 — N/A
Degenerative Disc Disease Research Study Groups: Platelet treatment, Sham procedure
Degenerative Disc Disease Clinical Trial 2023: Platelet lysate (PL) Highlights & Side Effects. Trial Name: NCT05287867 — N/A
Platelet lysate (PL) (Platelet-based Treatment) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05287867 — N/A
Degenerative Disc Disease Patient Testimony for trial: Trial Name: NCT05287867 — N/A
~14 spots leftby Jun 2025